Investor profile
SR One Capital Management
VC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
SR One is a transatlantic biotechnology venture capital firm that takes a 'back-and-build' approach to investing — partnering with founders and entrepreneurs to translate innovative science into medicines. The firm focuses on companies with strong underlying fundamentals, clearly defined development pathways, and novel approaches to addressing diseases with significant unmet medical needs, spanning oncology, immunology, rare diseases, cardiometabolic, neuropsychiatry, and infectious disease. SR One invests in both private and public companies across North America and Europe, with typical capital requirements of $30–$40 million per investment, and provides strategic, operational, and financial support through multiple value-creation inflection points. An Opportunities Fund also targets later-stage follow-on financings and select public biotech companies at attractive valuations.
Notable quotes
“At SR One we seek to partner with founders and entrepreneurs whose ambition is to rewrite the medical textbooks across a wide range of disease areas and modalities.”
“SR One's model is built upon active collaboration and our ability to roll up our sleeves and help build value through multiple inflection points. We seek to partner with entrepreneurs building elite biotechnology companies, and we look forward to the potential development of new medicines for patients that Fund II may help bring to the market.”
“SR One's mission is to work as a true partner with entrepreneurs to help bring their vision to reality. It is always humbling to work with the best minds in the ecosystem to meet the ongoing significant unmet needs in medicine and healthcare.”
Team
Rajeev Dadoo, PhD
COO & Managing Partner
Jake Nunn
Partner
Mahesh Kudari, MD
Partner
Katarina Pance, PhD
Partner
Amit Shah, MD
Partner
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Immutrin | Series A | $86m | 2026-03-24 |
| Poplar Therapeutics | Seed | — | 2026-03-03 |
| Windward Bio | Series B | — | 2026-05-04 |
| Arcellx | Series B | — | — |
| CRISPR Therapeutics | Series A | — | — |
| Morphic Therapeutic | Series B | — | — |
| Alumis | Series B | — | — |
| Design Therapeutics | Series B | — | — |
| Principia Biopharma | Series A | — | — |
| HotSpot Therapeutics | Series A | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| OrbiMed | 10 |
| HBM Healthcare Investments | 6 |
| Novo Holdings | 6 |
| RA Capital Management | 5 |
| New Enterprise Associates (NEA) | 5 |
| Atlas Venture | 4 |
Fit check
Is SR One Capital Management a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit